Imunon Appoints Stacy R. Lindborg as New President and CEO
IMUNON Appoints Stacy R. Lindborg As President And CEO, Effective May 13, 2024
Assumes leadership role as Company anticipates multiple near-term clinical milestonesBrings extensive leadership and experience in drug development and business strategyLAWRENCEVILLE, N.J., May 08, 20
Express News | Imunon Appoints Director DR. Stacy R. Lindborg as President and CEO
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
PDF Version Assumes leadership role as Company anticipates multiple near-term clinical milestonesBrings extensive leadership and experience in drug development and business strategyLAWRENCEVILLE,
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
PDF Version LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and nex
12 Health Care Stocks Moving In Friday's After-Market Session
GainersBluejay Diagnostics (NASDAQ:BJDX) shares increased by 11.0% to $0.73 during Friday's after-market session. The company's market cap stands at $1.9 million. China Pharma Holdings, Inc. Common St
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
By Chris Wack Imunon shares rose after the company received clearance from the U.S. Food and Drug Administration to begin a Phase 1 clinical trial with a seasonal Covid-19 booster vaccine. Shares we
Express News | IMUNON's IND Application Cleared By FDA To Begin Human Testing Of IMNN-101
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101
PDF Version Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarterLAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IM
Express News | Imunon Reports Compliance With Nasdaq Listing Requirements
IMUNON Reports Compliance With Nasdaq Listing Requirements
PDF Version LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on developing DNA-
Imunon Withdraws Filing for Securities Offering
Imunon Withdraws Filing for Securities Offering
Express News | Imunon Files FormRW, Co Determined Not To Pursue The Public Offering To Which The Registration Statement Relates. The Registration Statement Has Not Been Declared Effective By The SEC, And The Registrant Confirms That No Securities Have Been Sold Pursuant
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersMSP Recovery (NASDAQ:LIFW) stock increased by 61.9% to $1.08 during Tuesday's pre-market session. The company's market cap stands at $15.9 million. Serina Therapeutics (AMEX:SER) stock moved up
Express News | Imunon Shares Are Trading Higher After Hc Wainwright & Co Maintained a Buy Rating on the Stock and Raised Its Price Target From $12 to $13
Imunon Is Maintained at Buy by HC Wainwright & Co.
Imunon Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Imunon, Raises Price Target to $13
Imunon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 692.68% HC Wainwright & Co. $12 → $13 Maintains Buy 03/13/2024 631.71% HC Wainwright & Co. → $1
No Data